Pfizer Research and Development Expenses 2006-2020 | PFE

Pfizer annual/quarterly research and development expenses history and growth rate from 2006 to 2020. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Pfizer research and development expenses for the quarter ending September 30, 2020 were $2.360B, a 3.37% increase year-over-year.
  • Pfizer research and development expenses for the twelve months ending September 30, 2020 were $9.038B, a 9.08% increase year-over-year.
  • Pfizer annual research and development expenses for 2019 were $8.65B, a 8.04% increase from 2018.
  • Pfizer annual research and development expenses for 2018 were $8.006B, a 4.2% increase from 2017.
  • Pfizer annual research and development expenses for 2017 were $7.683B, a 2.65% decline from 2016.
Pfizer Annual Research and Development Expenses
(Millions of US $)
2019 $8,650
2018 $8,006
2017 $7,683
2016 $7,892
2015 $7,690
2014 $8,393
2013 $6,678
2012 $7,482
2011 $8,681
2010 $9,483
2009 $7,824
2008 $7,945
2007 $8,089
2006 $7,599
2005 $7,256
Pfizer Quarterly Research and Development Expenses
(Millions of US $)
2020-09-30 $2,360
2020-06-30 $2,132
2020-03-31 $1,724
2019-12-31 $2,822
2019-09-30 $2,283
2019-06-30 $1,842
2019-03-31 $1,703
2018-12-31 $2,458
2018-09-30 $2,008
2018-06-30 $1,797
2018-03-31 $1,743
2017-12-31 $2,315
2017-09-30 $1,865
2017-06-30 $1,787
2017-03-31 $1,716
2016-12-31 $2,532
2016-09-30 $1,881
2016-06-30 $1,748
2016-03-31 $1,731
2015-12-31 $2,349
2015-09-30 $1,722
2015-06-30 $1,734
2015-03-31 $1,885
2014-12-31 $3,209
2014-09-30 $1,802
2014-06-30 $1,759
2014-03-31 $1,623
2013-12-31 $1,811
2013-09-30 $1,627
2013-06-30 $1,530
2013-03-31 $1,710
2012-12-31 $1,933
2012-09-30 $1,887
2012-06-30 $1,600
2012-03-31 $2,062
2011-12-31 $2,183
2011-09-30 $2,176
2011-06-30 $2,231
2011-03-31 $2,091
2010-12-31 $2,893
2010-09-30 $2,188
2010-06-30 $2,181
2010-03-31 $2,221
2009-12-31 $2,792
2009-09-30 $1,632
2009-06-30 $1,695
2009-03-31 $1,705
2008-12-31 $2,303
2008-09-30 $1,885
2008-06-30 $1,966
2008-03-31 $1,791
2007-12-31 $2,260
2007-09-30 $1,999
2007-06-30 $2,165
2007-03-31 $1,665
2006-12-31 $2,412
2006-09-30 $1,902
2006-06-30 $1,742
2006-03-31 $1,543
2005-12-31 $1,923
2005-09-30 $1,739
2005-06-30 $1,830
2005-03-31 $1,764
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $206.939B $51.750B
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $379.086B 17.89
Roche Holding AG (RHHBY) Switzerland $285.787B 0.00
Novartis AG (NVS) Switzerland $205.434B 15.66
Merck (MRK) United States $202.049B 13.84
AbbVie (ABBV) United States $185.181B 10.70
Novo Nordisk (NVO) Denmark $159.043B 25.39
Eli Lilly (LLY) United States $141.038B 21.34
AstraZeneca (AZN) United Kingdom $138.080B 27.26
Sanofi (SNY) $128.037B 15.22
GlaxoSmithKline (GSK) United Kingdom $92.991B 12.32
Bayer (BAYRY) Germany $55.438B 8.35
H Lundbeck (HLUYY) Denmark $6.160B 10.78
Innoviva (INVA) United States $1.100B 5.02